LGD-4033, Ligandrol for another name, is a synthetic compound under the Selective Androgen Receptor Modulator (SARM). This compound is structurally distinct from anabolic steroids and is designed to bind selectively to androgen receptors, particularly in muscle and bone tissues. Its selective interaction is a key focus in research that examines targeted receptor activity while limiting effects in non-target tissues.

Mechanism of Action

LGD 4033 injectable is studied in research settings due to its significant affinity for androgen receptors in skeletal muscle and bone.

Once connected, it may have an impact on gene expression pathways related to protein regulation and tissue structure. These pathways are often examined in studies on tissue maintenance and anabolic signaling.

In controlled animals, preclinical results have demonstrated dose-dependent alterations in bone-related indicators and lean tissue characteristics. The pharmacokinetic characteristics of LGD-4033, including its half-life, receptor affinity, and low interaction with pathways like estrogen-related conversion or dihydrotestosterone (DHT), are also being investigated.

Properties of LGD-4033

• Molecular Formula: C14H12F6N2O
• Molecular Weight: 338.25 g/mol
• CAS Number: 1165910-22-4
• PubChem CID: 44137675
• IUPAC Name: 4-[(2R)-2-[(1R)-2,2,2-trifluoro-1-hydroxyethyl]pyrrolidin-1-yl]-2-(trifluoromethyl)benzonitrile
• Synonyms: LGD-4033, Ligandrol, VK-5211

Research Applications

Selective Receptor Binding Studies

LGD-4033 is widely used to study selective androgen receptor binding in muscle and bone tissues. These studies focus on receptor specificity and targeted signaling in controlled models.

Muscular Tissue Research

Research includes examining pathways related to protein regulation and lean tissue structure. Injectable LGD is often used to observe how receptor activation may influence measurable changes in muscle-related parameters.

Skeletal Research

This compound is also studied in relation to bone signaling processes, including structural maintenance and density-related markers in experimental models.

Pharmacokinetic Studies

LGD-4033 is examined for its absorption, distribution, and duration of activity. Research often focuses on its half-life and receptor affinity in controlled environments.

Comparative SARM Research

LGD-4033 is frequently evaluated alongside other SARMs to compare selectivity, potency, and signaling behavior. These comparisons support structure–activity research.

Why Source LGD-4033 from Behemoth Labz?

Behemoth Labz provide LGD-4033 Injactable for sale for laboratory and research use. 

Our LGD-4033 (injectable) is synthesized and batch-tested. This has been the practice of Behemoth Labz for years to ensure consistency, accuracy, and integrity of the research compounds.

We can provide you with certificates of analysis (COAs) for transparency and verification. Just message the support team anytime at support@behemothLabz.com | (307) 429-0990. 

Disclaimer: This material is provided for educational and laboratory research purposes only. These compounds are not approved for human or veterinary use. Product packaging and labeling may vary. By purchasing, customers agree to the company’s terms and conditions.

References

• Basaria, S., et al. The safety, pharmacokinetics, and effects of LGD-4033… Journal of Gerontology (2013).
• Dalton, J. T., et al. Selective androgen receptor modulators… Journal of Cachexia, Sarcopenia and Muscle (2011).
• Narayanan, R., et al. SARMs in preclinical and clinical development (2008).